Page last updated: 2024-08-24

atorvastatin and organophosphonates

atorvastatin has been researched along with organophosphonates in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cable, EE; Chi, B; Erion, MD; Fujitaki, JM; Ito, BR; Linemeyer, DL; MacKenna, DA; Song, X; van Poelje, PD; Wilker, CE; Zhang, BH	1
de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ	1

Trials

1 trial(s) available for atorvastatin and organophosphonates

Article	Year
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. British journal of clinical pharmacology, 2012, Volume: 74, Issue:2 Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir	2012

Article

Year

Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

British journal of clinical pharmacology, 2012, Volume: 74, Issue:2

Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir

2012

Other Studies

1 other study(ies) available for atorvastatin and organophosphonates

Article	Year
Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. British journal of pharmacology, 2009, Volume: 156, Issue:3 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Hypercholesterolemia; Macaca fascicularis; Male; Organophosphonates; Phenols; Prodrugs; Pyrroles; Rabbits; Thyroid Hormone Receptors beta	2009

Article

Year

Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.

British journal of pharmacology, 2009, Volume: 156, Issue:3

Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Hypercholesterolemia; Macaca fascicularis; Male; Organophosphonates; Phenols; Prodrugs; Pyrroles; Rabbits; Thyroid Hormone Receptors beta

2009